April 28th 2025
BMI, serum albumin, and G8 screening tool scores were all factors correlated with the likelihood of experiencing a grade 3 or higher AE.
December 17th 2024
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
View More
Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights
View More
PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies
View More
Medical Crossfire®: Precision Medicine in Glioma Treatment—Integration of Molecular Profiling to Inform Targeted Therapies
View More
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options
View More
8th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes
View More
Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care
View More
Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma
View More
Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Polatuzumab Vedotin Plus R-mini-CHOP Does not Increase High-Grade AEs in DLBCL
June 10th 2023Replacing vincristine with polatuzumab vedotin in R-mini-CHOP, although it hasn’t increased grade 3/4 hematologic toxicity, may increase gastrointestinal adverse effects in a cohort of frail patients with diffuse large B-cell lymphoma.
Tocilizumab May Reduce CRS Recurrence in Teclistamab-Treated Multiple Myeloma
May 12th 2023Findings from the phase 1/2 MajesTEC-1 trial suggest that preemptively planning and promptly managing cytokine release syndrome with supportive care in patients with multiple myeloma treated with T-cell–engaging bispecific antibodies may be beneficial.
Abatacept Combo May Reduce Immunotherapy-Related Myotoxicity in Cancer
March 8th 2023Abatacept plus ruxolitinib and screenings for concomitant respiratory muscle failure may be effective in reducing the rate of mortality related to immune checkpoint inhibitor–associated myocarditis among patients with cancer.
FDA Approves Pegfilgrastim Biosimilar to Mitigate Febrile Neutropenia From Chemo
March 6th 2023A prefilled autoinjector presentation of pegfilgrastim-cbqv, a pegfilgrastim biosimilar, has been approved by the FDA for patients with cancer undergoing chemotherapy who may experience febrile neutropenia.
NCCN Guidelines Update Includes Injection for Cisplatin Ototoxicity in AYAs
February 14th 2023A medical oncologist and research audiologist from St. Jude Children’s Research Hospital discuss how sodium thiosulfate injection may improve quality of life by preventing cisplatin-associated ototoxicities in pediatric patients with localized non-metastatic tumors, although more research is needed.